Transcatheter Aortic and Mitral Valve Implantation (TAMVI) in Native Rheumatic Valves.
A 68-year-old female with moderate to severe aortic stenosis and severe mitral stenosis, deemed too high risk for surgery (STS mortality risk = 12.3%) with a porcelain aorta, was successfully treated with a transcatheter aortic and mitral valve implantation (TAMVI) via a transapical approach. A 23 mm Sapien valve (Edwards Lifesciences, Irvine, CA, USA) was placed in the aortic position and a 29 mm inverted Sapien valve (Edwards Lifesciences) in the mitral position.
Division of Cardiothoracic Surgery, Albany Medical Center, Albany, New York.
Adanna C
AC
Akujuo
Division of Cardiothoracic Surgery, Albany Medical Center, Albany, New York.
Sophia L
SL
Dellis
Division of Cardiothoracic Surgery, Albany Medical Center, Albany, New York.
Lewis W
LW
Britton
Division of Cardiothoracic Surgery, Albany Medical Center, Albany, New York.
Edward V
EV
Bennett
D000368:Aged; D000818:Animals; D001024:Aortic Valve Stenosis / Q000175:diagnosis / Q000601:surgery*; D017548:Echocardiography, Transesophageal; D005260:Female; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000379:methods*; D006801:Humans; D008946:Mitral Valve Stenosis / Q000175:diagnosis / Q000601:surgery*; D016343:Monitoring, Intraoperative; D012214:Rheumatic Heart Disease / Q000601:surgery*; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed; D065467:Transcatheter Aortic Valve Replacement / Q000379:methods*; D016896:Treatment Outcome